Ocugen (OCGN) Set to Announce Quarterly Earnings on Friday

Ocugen (NASDAQ:OCGN) is set to issue its quarterly earnings data before the market opens on Friday, November 8th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Ocugen (NASDAQ:OCGN) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. The company had revenue of $1.14 million for the quarter. During the same quarter in the prior year, the firm posted ($0.10) earnings per share. On average, analysts expect Ocugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ocugen Stock Down 6.5 %

Shares of Ocugen stock opened at $0.91 on Friday. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.09. The company’s fifty day simple moving average is $1.07 and its two-hundred day simple moving average is $1.37. The company has a market cap of $262.24 million, a P/E ratio of -4.79 and a beta of 3.70. Ocugen has a 12-month low of $0.35 and a 12-month high of $2.11.

Analyst Upgrades and Downgrades

OCGN has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Ocugen in a research report on Wednesday, October 23rd. Maxim Group initiated coverage on shares of Ocugen in a research report on Tuesday, October 15th. They issued a “buy” rating and a $4.00 target price on the stock.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.